OPPORTUNITY RECOGNITION IN THE VETERINARY PHARMACEUTICAL INDUSTRY

TF19

Silva, N. T. R. (1); nairatrs@fcfrp.usp.br

Takahashi, V. P. (2)

(1)Departamento de Ciências Farmacêuticas, Faculdade de Ciências Farmacêuticas de Ribeirão Preto - FCFRP/USP, Ribeirão Preto. (2) Departamento de Ciências Farmacêuticas, Faculdade de Ciências Farmacêuticas de Ribeirão Preto- FCFRP/USP, Ribeirão Preto.

Brazil is one of the five largest veterinarian markets throughout the world and a major exporter of beef and chicken. The country concentrates the second largest population of pets in the world. It is increasingly expanding the market for animal health because the growing population of pets as "family members”, health and careful monitoring particularly for vaccination and reducing the use of antibiotics to promote growth. So a growing demand for veterinary pharmaceuticals has driven the development of new products and technologies in the industry, making the ability to innovate a fundamental requirement for the competitive edge of enterprises. The need for introduction of new drugs and / or drugs to a multitude of diseases / emerging zoonoses, control of pests and diseases as cancer, mainly in the pet segment, coupled with the need for innovation to support businesses in the market highlight the importance of identifying opportunities. As a result, the goal of work is to identify the factors that influence the link technology-market in the veterinary pharmaceutical industry, identifying the market conditions governing the effect of these factors and analysing the external environment of the industry. Data collection through Research Desk, i.e., bibliographic searches in magazines, publications and technical expertise, dissertations and theses, information from national government, laws, unions, professional associations, etc. Also theoretical concepts were explored in academic books and scientific papers that formed the theoretical basis for the grounds and construction of the project, and for setting goals. Results: The trends in technological innovations in products and processes are similar to those of human therapeutic as verified by newer drugs launched as: the Reconcile (fluoxetine hydrochloride) launched by Eli Lilly for dogs suffering from separation anxiety, and Slentrol (dirlotapide), of Pfizer Inc, to reduce canine obesity. The regulatory framework in the country, set up by the Ministry of Agriculture and Livestock (MAPA), is in the process of improvement verified by the constant meetings between representatives of the National Association of Pharmaceutical Laboratories (ALANAC) and MAPA. These changes in legislation may be sources of opportunities. Also there was a trend in the use of phytomedicines in the treatment of cattle in the management of the so-called organic beef. The objective was achieved with the development of a range of pharmaceutical and veterinary source identification of opportunities for new products and business. The main sources are: converging technologies, changes in the industry; customers; demographic changes; technological change; legislative and regulatory environment; competitors; economic environment; patents, scientific articles; fairs, exhibitions and conferences. (Financial suport CNPQ - Brasil)